Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Blood Rev. 2023 Jul;60:101071. doi: 10.1016/j.blre.2023.101071. Epub 2023 Mar 3.
Peripheral T-cell lymphomas (PTCLs) are a diverse and uncommon type of lymphoid malignancies with a dismal prognosis. Recent advances in genomic studies have shown recurring mutations that are changing our knowledge of the disease's molecular genetics and pathogenesis. As such, new targeted therapies and treatments to improve disease outcomes are currently being explored. In this review, we discussed the current understanding of the nodal PTCL biology with potential therapeutic implications and gave our insights on the promising novel therapies that are currently under study such as immunotherapy, chimeric antigen receptor T-cell therapy, and oncolytic virotherapy.
外周 T 细胞淋巴瘤(PTCLs)是一种异质性和罕见的淋巴恶性肿瘤,预后不良。近年来,基因组研究的进展显示出反复出现的突变,正在改变我们对该疾病分子遗传学和发病机制的认识。因此,目前正在探索新的靶向治疗方法和治疗方法来改善疾病结局。在这篇综述中,我们讨论了目前对结外 PTCL 生物学的理解及其潜在的治疗意义,并对目前正在研究的有前途的新型治疗方法,如免疫疗法、嵌合抗原受体 T 细胞疗法和溶瘤病毒疗法,提出了我们的见解。